iDD biotech Enters Worldwide Exclusive Licence Concerning Antibodies and Patents Related to CK8

iDD biotech Enters Worldwide Exclusive Licence Concerning Antibodies and Patents Related to CK8


CK8 is expressed at the cell surface in cancer cells , in particular in colon cancer but also in head and neck carcinoma, in glioma as well as in lung cancers. iDD biotech, together with Lyon Cancer Research Center , hosted by the Centre Leon Berard , has developed humanized MAb targeting eCK8 and has gained spectacular in-vivo POC with tumour shrinkage and massive necrosis.



from Biotech News